SANA (Sana Biotechnology) Payments of Debt: $-0.09 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SANA Sana Biotechnology Inc SANA
32 GF Score
Price $3.85
! 1 Warning Sign
View Full Analysis

What is Sana Biotechnology Payments of Debt?

Sana Biotechnology SANA -1.66% 32 Payments of Debt is $-0.09 Mil as of Jun. 2026. GuruFocus rates SANA with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Sana Biotechnology's Payments of Debt for the three months ended in Jun. 2026 was $0.00 Mil.

Sana Biotechnology's Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.09 Mil.

Sana Biotechnology Payments of Debt Related Terms

Sana Biotechnology Payments of Debt Historical Data

* Premium members only.

The historical data trend for Sana Biotechnology's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sana Biotechnology Payments of Debt Chart

Sana Biotechnology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -0.35

Sana Biotechnology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.09 0.00
SANA
32GF Score
Sana Biotechnology Inc SANA
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sana Biotechnology Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $-0.09 Mil mean?
Sana Biotechnology (SANA) has a Payments of Debt of $-0.09 Mil as of Jun. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Sana Biotechnology and its competitors.
Is Sana Biotechnology's Payments of Debt too high?
Sana Biotechnology's current Payments of Debt is $-0.09 Mil. Overall, Sana Biotechnology has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Sana Biotechnology's Payments of Debt compare to APMD and ODTX?
Sana Biotechnology's Payments of Debt of $-0.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Sana Biotechnology and its competitors. Sana Biotechnology's current Payments of Debt is $-0.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sana Biotechnology stock overvalued right now?
Sana Biotechnology (SANA) has a current Payments of Debt of $-0.09 Mil. The current Payments of Debt is $-0.09 Mil. Sana Biotechnology's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Sana Biotechnology (SANA), the current Payments of Debt is $-0.09 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sana Biotechnology Business Description

Address 188 East Blaine Street, Suite 350, Seattle, WA, USA, 98102
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
32GF Score

Get the complete analysis for SANA

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.85
Price